These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

222 related articles for article (PubMed ID: 36156186)

  • 1. A cost-effectiveness analysis of capecitabine maintenance therapy versus routine follow-up for early-stage triple-negative breast cancer patients after standard treatment from a perspective of Chinese society.
    Li JB; Lin ZC; Wong MCS; Wang HHX; Li M; Li S
    BMC Med; 2022 Sep; 20(1):320. PubMed ID: 36156186
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cost-effectiveness of Maintenance Capecitabine and Bevacizumab for Metastatic Colorectal Cancer.
    Sherman SK; Lange JJ; Dahdaleh FS; Rajeev R; Gamblin TC; Polite BN; Turaga KK
    JAMA Oncol; 2019 Feb; 5(2):236-242. PubMed ID: 30489611
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cost-effectiveness analysis of tumor-infiltrating lymphocytes biomarkers guiding chemotherapy de-escalation in early triple-negative breast cancer.
    Li S; Liu Y; Zhang P; Wang M; Sun L
    Cancer Med; 2023 Nov; 12(22):21001-21012. PubMed ID: 37964682
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cost-effectiveness analysis of utidelone plus capecitabine for metastatic breast cancer in China.
    Liao M; Jiang Q; Hu H; Han J; She L; Yao L; Ding D; Huang J
    J Med Econ; 2019 Jun; 22(6):584-592. PubMed ID: 30808230
    [No Abstract]   [Full Text] [Related]  

  • 5. Cost-effectiveness analysis of capecitabine plus bevacizumab versus capecitabine alone in elderly patients with previously untreated metastatic colorectal cancer from Chinese societal perspective.
    Zhang PF; Wen F; Zhou J; Huang JX; Zhou KX; Wu QJ; Wang XY; Zhang MX; Liao WT; Li Q
    Clin Transl Oncol; 2020 Jan; 22(1):103-110. PubMed ID: 31062173
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cost-effectiveness of capecitabine and bevacizumab maintenance treatment after first-line induction treatment in metastatic colorectal cancer.
    Franken MD; van Rooijen EM; May AM; Koffijberg H; van Tinteren H; Mol L; Ten Tije AJ; Creemers GJ; van der Velden AMT; Tanis BC; Uyl-de Groot CA; Punt CJA; Koopman M; van Oijen MGH
    Eur J Cancer; 2017 Apr; 75():204-212. PubMed ID: 28237866
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cost-effectiveness analysis of capecitabine maintenance therapy plus best supportive care vs. best supportive care alone as first-line treatment of newly diagnosed metastatic nasopharyngeal carcinoma.
    Han J; Lan X; Tian K; Shen X; He J; Chen N
    Front Public Health; 2022; 10():1086393. PubMed ID: 36777769
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Neratinib plus capecitabine versus lapatinib plus capecitabine as the third-line therapy for HER2-positive metastatic breast cancer in China: a cost-effectiveness analysis.
    Wu Y; Dong Z; Wang J; Fang Q
    BMJ Open; 2022 Nov; 12(11):e065299. PubMed ID: 36379662
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cost-Effectiveness and Net Monetary Benefit of Olaparib Maintenance Therapy Versus No Maintenance Therapy After First-line Platinum-based Chemotherapy in Newly Diagnosed Advanced BRCA1/2-mutated Ovarian Cancer in the Italian National Health Service.
    Armeni P; Borsoi L; Fornaro G; Jommi C; Colombo N; Costa F
    Clin Ther; 2020 Jul; 42(7):1192-1209.e12. PubMed ID: 32591103
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of Capecitabine Maintenance Therapy Using Lower Dosage and Higher Frequency vs Observation on Disease-Free Survival Among Patients With Early-Stage Triple-Negative Breast Cancer Who Had Received Standard Treatment: The SYSUCC-001 Randomized Clinical Trial.
    Wang X; Wang SS; Huang H; Cai L; Zhao L; Peng RJ; Lin Y; Tang J; Zeng J; Zhang LH; Ke YL; Wang XM; Liu XM; Chen QJ; Zhang AQ; Xu F; Bi XW; Huang JJ; Li JB; Pang DM; Xue C; Shi YX; He ZY; Lin HX; An X; Xia W; Cao Y; Guo Y; Su YH; Hua X; Wang XY; Hong RX; Jiang KK; Song CG; Huang ZZ; Shi W; Zhong YY; Yuan ZY;
    JAMA; 2021 Jan; 325(1):50-58. PubMed ID: 33300950
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cost-Effectiveness Analysis of Bevacizumab plus Paclitaxel versus Bevacizumab plus Capecitabine for HER2-Negative Locally Recurrent or Metastatic Breast Cancer.
    Wu Q; Wang X; Zhang M; Liao W; Wang F; Li Q
    Oncol Res Treat; 2020; 43(4):153-159. PubMed ID: 32187596
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cost-effectiveness of 12 months of capecitabine as adjuvant chemotherapy for stage III colon cancer: preplanned cost-effectiveness analysis of the JFMC37-0801 study.
    Shibahara H; Shiroiwa T; Ishiguro M; Nakamura M; Hasegawa J; Yamaguchi S; Masuda Y; Sakamoto J; Tomita N; Fukuda T
    Eur J Health Econ; 2022 Sep; 23(7):1159-1171. PubMed ID: 35072852
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cost-utility analysis of the newly recommended adjuvant chemotherapy for resectable gastric cancer patients in the 2011 Chinese National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology: Gastric Cancer.
    Chongqing T; Liubao P; Xiaohui Z; Jianhe L; Xiaomin W; Gannong C; Siying W; Lihui O; Ziying Z
    Pharmacoeconomics; 2014 Mar; 32(3):235-43. PubMed ID: 23709451
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Early stage cost-effectiveness analysis of a BRCA1-like test to detect triple negative breast cancers responsive to high dose alkylating chemotherapy.
    Miquel-Cases A; Steuten LM; Retèl VP; van Harten WH
    Breast; 2015 Aug; 24(4):397-405. PubMed ID: 25937263
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The clinical effectiveness and cost-effectiveness of cardiac resynchronisation (biventricular pacing) for heart failure: systematic review and economic model.
    Fox M; Mealing S; Anderson R; Dean J; Stein K; Price A; Taylor RS
    Health Technol Assess; 2007 Nov; 11(47):iii-iv, ix-248. PubMed ID: 17999842
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Topotecan, pegylated liposomal doxorubicin hydrochloride and paclitaxel for second-line or subsequent treatment of advanced ovarian cancer: a systematic review and economic evaluation.
    Main C; Bojke L; Griffin S; Norman G; Barbieri M; Mather L; Stark D; Palmer S; Riemsma R
    Health Technol Assess; 2006 Mar; 10(9):1-132. iii-iv. PubMed ID: 16545208
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cost-effectiveness analysis of niraparib maintenance therapy in Chinese patients with platinum-sensitive recurrent ovarian cancer.
    Qiu Y; Zha J; Ma A; Zhou T
    Gynecol Oncol; 2023 Jul; 174():175-181. PubMed ID: 37209503
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Adefovir dipivoxil and pegylated interferon alfa-2a for the treatment of chronic hepatitis B: a systematic review and economic evaluation.
    Shepherd J; Jones J; Takeda A; Davidson P; Price A
    Health Technol Assess; 2006 Aug; 10(28):iii-iv, xi-xiv, 1-183. PubMed ID: 16904047
    [TBL] [Abstract][Full Text] [Related]  

  • 19. First-Line Treatment With Atezolizumab Plus Nab-Paclitaxel for Advanced Triple-Negative Breast Cancer: A Cost-Effectiveness Analysis.
    Weng X; Huang X; Li H; Lin S; Rao X; Guo X; Huang P
    Am J Clin Oncol; 2020 May; 43(5):340-348. PubMed ID: 32028340
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The effectiveness and cost-effectiveness of carmustine implants and temozolomide for the treatment of newly diagnosed high-grade glioma: a systematic review and economic evaluation.
    Garside R; Pitt M; Anderson R; Rogers G; Dyer M; Mealing S; Somerville M; Price A; Stein K
    Health Technol Assess; 2007 Nov; 11(45):iii-iv, ix-221. PubMed ID: 17999840
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.